On the other side of the world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, it wasn’t sitting on a shelf when IPIX picked it up for pennies on the dollar. It had just finished Phase 2a testing and Polymedix was trying to raise money for Phase 2b. The CEO did a reverse split which scared away all possible financiers and investors, among several other reasons for bankruptcy. But, Brilacidin injectable for ABSSSI was still their leading drug.
Futures were down a little over 1000 on DJIA, and boom opened down over 2250. Instant circuit breaker pop.
There are two centers and 2 possible paths. The first is testing it as an antiviral. That’s not surprising since the other possible covid-19 antivirals have some serious side effects.
The control is those who are not treated with B. It’s called real world, in-field human testing under emergency protocols. Please read today’s PR again: “... confirmation of the testing schedule as well as procedures for the studies later this week.”
I’m surprised you are not familiar with this. Real world emergency protocols for deadly diseases with no current treatment. Current US covid-19 mortality is 4.2%. Worldwide it’s just over 2.4%.
Read it again. In that list there was only one treatment and it’s not testing in the US. The rest are vaccines and prophylactics.
That’s what the CDC is doing and that’s how it works. Your disagreement simply shows how little you know about the arena of outbreaks with no treatment available.
Back to even. Buy the dips.
How do you think they will be testing it? That’s why the criteria for candidates included phase 2 studies completed. It will be in patients by the end of April if not before the end of this month. If it works, use will be expanded, if not it will be dropped.
There she goes. Looks like .2 by noon.
Old complaint resolved, new complaint manufactured. Rinse/repeat.
To date US confirmed cases: 447, deaths 19.
That’s 4.2% mortality in US confirmed cases. Worldwide rate 2.3%. That’s the perspective. Coronavirus is now coast to coast. Cases are now from California to NYC, NYC to Florida, Florida to Houston, Denver and Phoenix.
Links:
https://www.worldometers.info/coronavirus/#countries
https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
“ That is not asking for much in the midst of a public health emergency ”
Actually, that is asking too much “in the midst of a public emergency.” No one needs to know that for a drug until it is proven effective or ineffective. Medical professionals working public emergencies certainly know this to be true.
What nonsense. Leo has been trying to fund B for low hanging fruit and has struggled. You have been here long enough to know that. So, now in hindsight you think he should have funded studies against SARS and MERS? Again, what nonsense.
All I’m saying is that there are already broad spectrum antibiotics in use and there are several alternatives to treating the gut microbiota.
Can’t disagree with all you say except for the microbiome issue. Aren’t there already broad spectrum drugs and treatments that destroy the gut microbiome? Isn’t that where fecal treatment comes in? Isn’t there already a treatment in use where your destroyed gut biome is replaced by your preserved gut biome? Gosh, I’m not a doctor so I don’t know anything about any of this.
One is delivered by inert enema solution; the other delivered by otherwise inert time release capsules/pills. Please explain how these are different other than one is swallowed and the other the somewhat uncomfortable other end. Also, logic dictates that B-UP won’t move forward until it’s clear that the pill won’t treat the entire colon to the anus. Again, and no one responded when I said this, doesn’t the UP licensee have first refusal on B-IBS?
We won’t know if it works next week. Probably know by the end of the month.
As soon as doctors see easing of respiratory distress B-IV will be reported and use expanded. At the same time, those testing will last B into an inhaler and see how that works. If Leo announces he’s ordering more B, that will be a strong clue.
All in all, worldwide distribution is a month to two months away.
Experts I’m in touch with are saying current measures are only to slow the spread of covid-19. Until there’s a vaccine, to stop the virus, this will be with us. In spite of what the USA CEO is saying, this isn’t going away with summer (see Australia and summer). This will be with us for a while.
“Is shipping this week” was last week means it was shipped, definitively.
IPIX is a micro cap, yes? He can sell up to $1 million in securities per year directly into the market. Yes? Not sure what the current regs say, but that’s my understanding, and the year is still young. The amount limit in direct stock sales may be higher than what I stated.
The PR last week said shipped. The rest of your post is nonsense.
If it’s in an inhaler form, then the RBL will begin with a confirmation mouse study. It would then need a quick safety study, much like the pill went through. I’m hoping they try IV on humans as they test the inhaler in mice. The RBL certainly has the facility and resources and funding to run several parallel studies.
To me it seems both the immunomodulatory and anti inflammatory properties are what NIAID and the CDC are most interested in. Twenty percent of all covid-19 patients suffer severe respiratory distress due to inflammation of the alveoli. Latest data shows 3.3% die. Antiviral activity would be a bonus.
Emergency measures for pandemics against which there are no prophylactic or treatment drugs. They are already doing it according to both the NYTimes and Washington Post. Several articles that included interviews with repatriated patients mentioned this. NIAID is behind the in-field experimental use of clinical stage drugs. Brilacidin is a clinical stage drug.
First must come treatment for covid-19 patients in the coming weeks. Most immediately, NIAID and CDC will examine current status of safety. If there is sufficient proof, then it will almost immediately be used on patients in a real-time, in-field assessment. Patients not treated with B will serve as real-time, authentic, clinical practice controls. Efficacy will be measured against those not treated or treated with other drugs.
Emergency measures testing differs from vaccine testing in that no vaccine is ever tested in field until safety is established, even under emergency measures. The CDC learned its lesson during the deadly swine flu outbreak in the 70’s. The Swine Flu vaccine was rushed into use with minimum safety tests. People died from the vaccine. That’s why there will be no covid-19 vaccine for at least 12 months and more likely 18.
In any case, we will know if B is effective against coronavirus symptoms long before a vaccine is available. Outcomes will include measurable reduction in severity of symptoms, reduction in secondary infections, reduction of swelling and damage to alveoli, reduction in recovery time. If it meets any combination of those outcomes, testing and use will be expanded.
Yep. Profit taking before lunch. We’ll see what happens after the bosses come back and relieve the trainees.
Now .17 is the wall. Lol
Here’s the translation for that Vietnamese article:
COVID-19 treatment: A new potential drug is being tested in the laboratory
Du Mien • 29/02/20 19:56 612 views
Innovation Pharmceuticals said on Thursday it will soon bring the new coronavirus potential drug to a regional biosafety laboratory for testing.
This potential drug is Brilacidin, capable of treating COVID-19 caused by a new virus.
Massachusetts-based Innovation Pharmceuticals said it has signed an agreement with one of the nation's 12 biosafety laboratories based at the university, to study Brilacidin as a treatment. New virus, and plans to bring Brilacidin to the laboratory in the coming days. Specific information about this lab was not disclosed.
Laboratory scientists will evaluate the potential anti-viral and anti-inflammatory properties of Brilacidin to combat viral infections, including SARS-CoV-2, the virus that causes COVID-19.
This potential drug will be tested with a number of infections along with other antiviral drugs.
The test can be completed within weeks of receiving Brilacidin, Innovation said in a press release.
The company says Brilacidin is a versatile compound with a broad therapeutic potential under a new chemical class called defensin-mimetic. An Nature review article on coronavirus suggests that immunomodulators such as Brilacidin could be a promising treatment for viruses, including SARS-CoV-2, when combined with Other antiviral drugs ,.
“The basic theory is that once the viral load is reduced, the body's natural immune response can be strengthened by Brilacidin after adjuvant therapy, so it is able to combat coronavirus complications well. more, ”the company said in a statement earlier in the week.
Innovation is also exploring cooperation with a government-funded virology laboratory in Asia to test Brilacidin, and has submitted a preliminary summary of the potential of Brilacidin, as a treatment. new coronavirus for the Advanced Biomedical Research and Development Agency.
A variety of other drugs are being tested as the virus spreads to new countries daily. The first case in South America was confirmed by Brazil on Wednesday (February 26) and seven other countries confirmed the first cases.
Gilead Science Inc.'s Remdesivir has been promoted as one of the strongest candidates to treat the new virus. It is being tested in tests in China and the United States. Chinese researchers are also testing Lopinavir and Ritonavir, two drugs commonly used to treat HIV, syndrome of human immunodeficiency virus infection, as well as Ritonavir and Ganovo.
On Thursday (February 27), Ascletis Pharma Inc. said three patients were discharged after being treated with Ganovo and Ritonavir. Favipiravir, approved for the treatment of influenza in several countries, has been participating in clinical development for COVID-19 this month.
The initial OM data didn’t clear/cure 100% of the patients. As I said, the next trial will include a control group. Yes, it’s the final absolute proof when one group has 100% efficacy and the control simply runs the disease’s eruption cycle. But, it’s silly to dismiss 100% treatment efficacy as invalid simply because a proof of concept trial was designed without a placebo or standard of care group.
Don’t need controls when the study showed 100% remission in all subjects. What a silly argument. The next study will be a controlled study—double-blind, small control group—because that’s what the FDA will want before approval.
Yes, agree. I was writing my post as you posted yours.
Alphasigma has first refusal for IBD, and is licensed only for UP and rectal issues. Yes? They signed cheaply knowing there was a targeting pill in development and that pill was likely to treat the entire lower bowel due to no absorption. Yes? And, further, an enema treatment would be second choice for physicians and patients if the enema was not vastly superior. This would be off-label, of course since AS would insist on their rights for on-label marketing. So, it would be not be in AS’s interest to exercise their rights? Or, perhaps sell the on-label rights to whoever got the IB platform for the pill.
Appears you are not familiar with emergency protocols in testing under pandemic threats. Phase 2 safety and indications of efficacy in the disease type are all that are necessary for direct to human testing. CDC and NIAID are already doing it for other drugs in the covid-19 population in California.
I think you are misreading the intended meaning. The intended meaning, it has collectively demonstrated those properties through phase 2 clinical testing, also collectively. The IBD pill is mentioned because there was a bridge study that included looking for markers for those 3 properties. Bridge studies confirm there are no changes in properties among possible delivery systems, so they “bridge” other advanced studies to new versions of a drug. Thus, Brilicidin phase 2 properties “bridge” to the new delivery. Is further clinical proof needed, yes. Are previous studies collectively assessed, again yes.
The drug is now at a Regional Biocontainment Center to see if it is worthy of advancing to clinical testing. In fact, because the US is now under a pandemic threat emergency, and Brilicidin has proven safety in humans, it’s likely it will be tested directly on covid-19 patients. The CDC has been doing this type of testing on the repatriated American coronavirus patients in California, according to yesterday’s NYTimes.
Seems those at NIAID and the CDC are not as nit-picky about collective data as many posters on stock blogs.
What do you think the trial tests were? Someone else will help you find this.
Worth reposting: Scientific Rationale for Brilacidin against Covid-19
https://ipharminc.us2.list-manage.com/track/click?u=9ed1a6b082ae8962468007971&id=fe02d76624&e=cf2405a235
Scientific Rationale for Brilacidin against CoV-19
https://ipharminc.us2.list-manage.com/track/click?u=9ed1a6b082ae8962468007971&id=fe02d76624&e=cf2405a235
So, what’s the volume now off the bounce? I’m thinking this one sticks, but who knows? MMs ran out of stock and they needed to cover a few hundred thousand shares in open (short) positions from the open. But, who knows?
Back filled the gap from yesterday. Let’s see what it does the rest of the day.
“BSL-4 Laboratories in the United States
There are currently 13 operational or planned BSL-4 facilities within the United States of America. These are listed below.”
https://fas.org/programs/bio/research.html#NatRegBioconLab
It comes down to misrepresenting BU:
“ nationwide.
The NBLs and RBLs are operated by the grant recipients, research institutions across the country. These labs support biodefense and emerging infectious diseases research as resources that provide lab space for basic research of dangerous pathogens and development of new vaccines and treatments. The NBLs are required to have BSL-4, BSL-3, and BSL-2 labs, animal facilities, insectary facilities, clinical facilities, and research support space. The RBLs are required to have BSL-3 and BSL-2 labs, animal facilities, and research support space. While fulfilling the need of researchers occupying the facility, the NBLs and RBLs can be used by other biodefense researchers within the region, particularly those within the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases. In addition, these labs are available to provide assistance to national, state, and local public health efforts during a biological attack.”
BU is a National Biocontainment Center. It is required to have BSL 4 labs, facilities and procedures in place. Regional facilities are not required.
https://fas.org/programs/bio/research.html#NatRegBioconLab